Clinical Utility of an Amniotic Membrane Allograft for Diabetic Foot Ulcer Wound Management
Key facts
- Who runs it
- Legacy Medical Consultants
- Where
- Chicago, Darien, Palm Springs, Pasadena, Pembroke Pines, Portland, San Francisco, and Vista, United StatesSee the 8 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 240 people, planned
- Started
- 30 Dec 2025
- Expected to end
- Jul 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Orion TM Amniotic Membrane Allograft
- Standard of Care (SOC)
- Record updated
- 28 August 2026
Who can take part
- Age
- 50 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 40 criteriaShow less
Who can take part
- Ambulatory patients ≥ 50 and ≤ 85 years of age
- Willing and able to provide informed consent
- Willing and able to comply with study requirements
- Presence of Wagner 1 and superficial Wagner 2 DFU extending at least through the dermis provided the DFU is located in the foot distal to the medial malleolus
- If multiple Wagner 1 and superficial Wagner 2 DFUs are present, the largest ulcer meeting DFU eligibility criteria will be selected as the index DFU in the study
- Index ulcer is able to be visualized and accurately measured with eKare Insights
- Non-study ulcers must be > 2 cm (.79 in.) from the index ulcer
- Index DFU identified ≥ 4 weeks prior to study screening and < 52 weeks from the date of informed consent
- Index DFU area > 1.0 cm2 (0.39 in.) and < 25 cm2 (9.84 in.) at screening and at Wound Management Period Visit #1
- Index DFU offloaded according to SOC for entire run-in period, prior to randomization
- Potential participant is under the care of a clinician for diabetic management and other medical conditions (the site PI may assist/direct the patient in the pre-screening period to obtain a PCP)
- Index foot has adequate circulation defined as meeting one (1) of the following within 30 days of screening:
- ABI ≥ 0.7 and ≤ 1.3 AND TBI > 0.7; B. Dorsum transcutaneous oxygen tension measurement (TcPO2) ≥ 40 mmHg; C. Arterial duplex with biphasic flow in BOTH the DP and PT arteries verified by PI and documented
Who cannot take part
- Treatment with an antibiotic impregnated primary dressing ≤ 4 weeks prior to study screening
- Treatment with immunosuppressants, including systemic corticosteroids for ≥ 2 weeks within 30 days prior to study screening, or are anticipated during study participation
- Any active cancer undergoing treatment ≤ 30 days prior to wound management visit #1 of the run-in period, or is anticipated during study participation
- Treatment with chemotherapy within 30 days of the first study wound management visit of the run-in period, or is anticipated during study participation
- Participation in an investigational device, biologic, or drug study currently or within 30 days of study wound management visit #1 of the run-in period
- Prior use of any advanced skin substitute product on the index ulcer within 60 days of visit #1 of the run-in period
- Patient is taking a cyclooxygenase-2 inhibitor (COX-2 inhibitor); such as, celecoxib (Celebrex, Consensi, Elyxyb), valdecoxib (Bextra), amlodipine (Consensi)
- Index foot ulcer documented to be caused by a medical condition other than diabetes
- Index ulcer is potentially or confirmed by biopsy to be cancerous
- Index ulcer site has undergone radiation therapy
- Active infection proximal to or at site of index ulcer
- Index foot ulcer reduced in area by ≥ 20% at the end of the 4-week run-in period
- Presence of active osteomyelitis or bone infection as verified by x-ray /MRI within 30 days of visit #1 of the run-in period
- Raynaud's disease
- Index ulcer was continued to be treated after visit #1 of the run-in period and/or anticipate treatment during study participation with any of the following prohibited therapies:; Biomedical or topical growth factor; Topical steroids applied to the index ulcer surface; On medications that are considered immune system modulators that could affect graft incorporation; Scarlet red dressing; Dakin's solution; Mafenide acetate; Tincoban; Zinc sulfate; Povidone-iodine solution; Polymyxin/nystatin; Chlorhexidine
- Autoimmune connective tissue disease
- End stage renal disease (ESRD)
- Presence of any condition which would seriously compromise the subject's ability to complete this study
- Known history of poor adherence to medical therapy and/or clinic appointments
- Diabetics with poor metabolic control, defined as HbA1c ≥ 12.0%, within 30 days of visit #1 of the run-in period
- Patient has serum creatinine > 2.5 mg/dL within 30 days of study wound management visit #1 of the run-in period
- Potential subject has five (5) or more DFUs and/or VLUs in the target limb
- DFU is secondary to Charcot neuroarthropathy
- Venous leg ulcers in diabetic patients
- Unreconstructible arterial ischemia which may lead to nonhealing
- Pregnant, or planning to become pregnant during the study
- Life expectancy < 1 year
Where in United States
- Rosalind Franklin University of Medicine and ScienceChicago, United States
- Stamford Health Medical GroupDarien, United States
- DPMGPalm Springs, United States
- Chesapeake Research GroupPasadena, United States
- Optimum Care Research CenterPembroke Pines, United States
- Oregon Health Science UniversityPortland, United States
- Center for Clinical Research Inc.San Francisco, United States
- ILD Research CenterVista, United States
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if use of Orion™, a dual-layer amniotic membrane allograft, in addition to standard wound care treatment can improve patient outcomes for people over the age of 50 with diabetic foot ulcers. The study aims to determine the incidence of complete wound closure at the end of 12 weeks of treatment. Researchers will compare the outcomes between a group of people treated with standard wound care and another group treated with standard wound care in addition to the amniotic membrane allograft to see if the amniotic membrane allograft improves wound healing.
Read full original descriptionShow less
During the study, participants will visit their doctor weekly over a 12 week period, which is standard for diabetic foot ulcer treatment procedures, and fill out a questionnaire measuring quality of life.
The 2 groups in the trial
- Standard of Care (SOC)Existing treatment, for comparison
Standard of care DFU wound management
- Amniotic Membrane plus Standard of CareTreatment being tested
Weekly application of Orion™ amniotic membrane allograft in addition to standard of care DFU wound management
Treatment: Orion TM Amniotic Membrane Allograft and Standard of Care (SOC)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Post-market Randomized Controlled Trial (RCT) to Demonstrate Clinical Utility of an Amniotic Membrane Allograft in Diabetic Foot Ulcer (DFU) Wound Management
- Record updated
- 28 August 2026